Tech Company Financing Transactions
Osprey Pharmaceuticals Funding Round
BDC Venture Capital, Burrill & Company and GeneChem participated in a $3.8 million Series A funding round for Osprey Pharmaceuticals. The financing round was announced on 5/27/2009.
Transaction Overview
Company Name
Announced On
5/27/2009
Transaction Type
Venture Equity
Amount
$3,800,000
Round
Series A
Investors
Proceeds Purpose
Proceeds purposes were not disclosed.
Company Information
Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
425 California Street 1300
San Francisco, CA 94104
USA
San Francisco, CA 94104
USA
Phone
Website
Email Address
Overview
Osprey Pharmaceuticals USA, together with its Montreal, Canada partner, Osprey Pharmaceuticals, Ltd., is developing a series of novel fusion protein therapeutics which selectively target and neutralize activated leukocytes that are implicated in a variety of inflammatory and immune disorders.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Jack Anthony
Chief Marketing Officer
Barbara Finck
General Manager
Laura McIntosh,
VP - Operations
John McDonald
Browse more venture capital transactions:
Prev: 5/27/2009: TeachStreet venture capital transaction
Next: 5/27/2009: CardiAQ Valve Technologies venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on funding rounds that are announced publicly. VC investment data records reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs